糖皮质激素治疗与IPF急性加重住院结局无关
该回顾性队列研究在UCSF医学中心电子健康记录中识别2010至2018年82例IPF急性加重(AE-IPF)患者,其中37例(45%)接受糖皮质激素治疗。倾向评分加权Cox模型显示激素治疗与院内死亡率无显著关联(调整HR 1.31,95%CI 0.26-6.55,P=0.74),但激素组总体生存率降低(HR 6.17,95%CI 1.35-28.14,P=0.019)。
要点
- AE-IPF患者使用糖皮质激素未改善院内死亡率。
- 激素治疗组总体生存率显著降低,需警惕潜在危害。
- 激素组更多需ICU监护和机械通气,提示适应证偏倚。
核心结论
- 糖皮质激素治疗未改善AE-IPF患者院内死亡率,且可能与总体生存率降低相关。
研究设计与样本
- 回顾性队列研究,基于UCSF医学中心2010年1月1日至2018年8月1日电子健康记录,采用编码算法识别并经病例验证,共纳入82例AE-IPF患者。
主要发现
- 82例AE-IPF患者中37例(45%)接受糖皮质激素治疗。
- 激素组更可能需要ICU级别护理和机械通气。
- 倾向评分加权调整后,激素治疗与院内死亡率无显著关联(调整HR 1.31,95%CI 0.26-6.55,P=0.74)。
- 激素治疗组总体生存率降低(HR 6.17,95%CI 1.35-28.14,P=0.019)。
临床怎么用
- 对AE-IPF患者使用糖皮质激素应权衡潜在危害,不应默认作为改善生存的手段。
局限性
- 为单中心回顾性观察性研究,样本量有限(82例),可能存在适应证混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: AE-IPF has profound prognostic implications, preceding approximately half of all IPF-related deaths. Despite this clinical significance, there are limited data to guide management decisions. Corticosteroids remain the mainstay of treatment despite a lack of strong supporting evidence and mounting concern that they may be harmful. We assessed the impact of corticosteroid therapy on in-hospital mortality in AE-IPF patients. METHODS: AE-IPF subjects were retrospectively identified in the UCSF medical centre's electronic health records from 1 January 2010 to 1 August 2018 using a code-based algorithm followed by case validation. The relationship between corticosteroid treatment and in-hospital mortality was assessed using a Cox model and a propensity score to control for confounding by indication. Secondary outcomes included hospital readmissions and overall survival. RESULTS: In total, 82 AE-IPF subjects were identified, of whom 37 patients (45%) received corticosteroids. AE-IPF subjects treated with corticosteroids were more likely to require ICU level care and mechanical ventilation. There was no statistically significant association between corticosteroid treatment and in-hospital mortality (propensity score weighted, adjusted HR: 1.31; 95% CI: 0.26-6.55; P = 0.74). Overall survival was reduced in AE-IPF subjects receiving corticosteroids (HR: 6.17; 95% CI: 1.35-28.14; P = 0.019). CONCLUSION: Our study found no evidence that corticosteroid use improves outcomes in IPF patients admitted to the hospital with acute exacerbation. Furthermore, corticosteroid use may contribute to reduced overall survival following an exacerbation. Observational cohort studies using larger real-world cohorts can more definitively assess the relationship between corticosteroid treatment and short-term outcomes in AE-IPF.
引用
- Farrand E, Vittinghoff E, Ley B, et al. Corticosteroid use is not associated with improved outcomes in acute exacerbation of IPF. Respirology. 2019. PMID: 31846126. doi:10.1111/resp.13753
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。